Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2008-10-24

FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Isentress (raltegravir) by Merck Sharp & Dohme LLC. The approval updates the product’s indication/label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Isentress (Raltegravir)

Snippet

SUPPL AP for ISENTRESS (RALTEGRAVIR)